CClinicalTrials.gg
CompletedNCT05200000Updated Feb 20, 2024

Wharton's Jelly Eye Drops in the Treatment of Chronic Keratitis

A Phase 1 interventional study of SygeLIX-Coll-T in Keratitis, Ulcerative and Corneal Ulcer, sponsored by TBF Genie Tissulaire. Completed at 6 sites in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by TBF Genie Tissulaire · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this open, non-comparative, multicenter trial is to assess the impact of eye drops made of Wharton's jelly extract in the treatment of chronic keratitis that failed available therapies.

02

Conditions studied

  • Keratitis, Ulcerative
  • Corneal Ulcer
03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Men or women between 18 and 70 years old.
  • Persistent corneal ulceration.
  • Resistance to medical treatment for more than one month or recurrence after medical treatment.
  • Patient who underwent a wash-out period of 15 days with no use of eye drops with preservative.
  • Patient with dry eye treatments that can be kept: tear substitutes, cyclosporine.
  • Informed and consenting patient.
  • Patient affiliated to a social security system or beneficiary of such a system.

Exclusion criteria

Exclusion Criteria:

  • Patient with active infectious or traumatic keratitis such as burns.
  • Patient with herpetic keratitis.
  • Patient currently wearing contact lens, including scleral lenses concomitant with the treatment.
  • Patient currently treated with NSAIDs in eye drops or any eye drops containing preservatives.
  • Patient treated with antibiotic, anti-viral or anti-parasitic eye drops; with autologous or allogeneic serum; with platelet derivatives; with eye drops claiming healing properties; with eye drops containing growth factors, hyaluronic acid or trehalose.
  • Patient with hypersensitivity to fluorescein.
  • Patient with identified causes for keratitis for which discontinuation of medical treatment is beneficial.
  • Monophthalmic patients.
  • Persons deprived of liberty by a judicial or administrative decision.
  • Adults who are subject to a legal protection measure or who are unable to express their consent.
  • Pregnant woman.
04

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    SygeLIX-Coll-T

    Extract of umbilical cord lining constituted of Wharton's jelly put in suspension in microvials. Instillation by the patient in the sick eye of 1 drop 5 times a days (morning, noon, afternoon, evening and bedtime) for 40 days.

    Biological: SygeLIX-Coll-T

Interventions

  • BiologicalSygeLIX-Coll-T

    Reconstituted suspension made of Trehalose and chemically treated, grinded, freeze-dried and sterilized Wharton's Jelly used by the patient as eye drops.

05

What researchers measure

Primary outcomes

  1. Absence of aggravated inflammatory signs, worsening of visual acuity or other side effect

    Inflammatory signs evaluated using a composite score on 66 points. Duration and intensity are evaluated for secretion, dry eyes, tearing, foreign body sensation, fluctuating vision, photophobia, burning sensation and lids edema. Duration is evaluated from a scale from 0: never to 4: all the time. Intensity is evaluated from a scale from 0: slight to 2: severe. Localization and intensity are evaluated for conjunctival edema, conjunctival redness and neovascularization. Localization is evaluated on a scale from 0: no reaction to 4: reaction present in the whole eye

    Time frame: Through study completion - average of 40 days

Secondary outcomes

  1. Re-epithelialization of the cornea

    Epithelialization assessed by the Oxford score after fluorescein instillation in the eye (0: no corneal staining to 5: severe corneal staining)

    Time frame: 7 days, 15 days, 40 days

  2. Improvement of dry eyes signs and symptoms

    Severity of dry eye evaluated using Ocular Surface Disease Index (OSDI) questionnaire

    Time frame: 7 days, 15 days, 40 days

  3. Improvement of visual acuity

    Visual acuity evaluated on Monoyer chart

    Time frame: 7 days, 15 days, 40 days

06

Study locations

6 sites
  • Hôpital Michallon, CHU de Grenoble
    La Tronche, 38700, France
  • Hôpital Gui de Chauliac, CHU de Montpellier
    Montpellier, 34295, France
  • Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
    Paris, 75012, France
  • Hôpital Fondation Adolphe de Rothschild
    Paris, 75019, France
  • Hôpital Charles-Nicolle, CHU de Rouen
    Rouen, 76000, France
  • Hôpital Nord, CHU de Saint-Etienne
    Saint-Priest-en-Jarez, 42270, France
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05200000
Lead sponsor
TBF Genie Tissulaire
Responsible party
Sponsor
First posted
Jan 20, 2022
Start date
Jan 8, 2020
Primary completion
Jun 20, 2023
Completion
Jun 20, 2023
Last update
Feb 20, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion